106 related articles for article (PubMed ID: 35842770)
1. ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells.
de Almeida BO; de Almeida LC; Costa-Lotufo LV; Machado-Neto JA
Cell Biol Int; 2022 Sep; 46(9):1433-1446. PubMed ID: 35842770
[TBL] [Abstract][Full Text] [Related]
2. Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs.
Fragiadaki M; Zeidler MP
J Biol Chem; 2018 Jun; 293(25):9570-9579. PubMed ID: 29695508
[TBL] [Abstract][Full Text] [Related]
3. ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.
Dhyani A; Machado-Neto JA; Favaro P; Saad ST
Eur J Cancer; 2015 Jan; 51(2):252-9. PubMed ID: 25483783
[TBL] [Abstract][Full Text] [Related]
4. ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway.
Liu XF; Han Q; Rong XZ; Yang M; Han YC; Yu JH; Lin XY
Int J Oncol; 2020 May; 56(5):1175-1185. PubMed ID: 32319569
[TBL] [Abstract][Full Text] [Related]
5. Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes.
Almeida BO; Machado-Neto JA
BMB Rep; 2020 Aug; 53(8):413-418. PubMed ID: 32635985
[TBL] [Abstract][Full Text] [Related]
6. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling.
Yao PA; Wu Y; Zhao K; Li Y; Cao J; Xing C
Cell Death Dis; 2022 Feb; 13(2):103. PubMed ID: 35110552
[TBL] [Abstract][Full Text] [Related]
7. ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT.
Yao P; Li Y; Shen W; Xu X; Zhu W; Yang X; Cao J; Xing C
Am J Cancer Res; 2018; 8(11):2311-2324. PubMed ID: 30555746
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
9. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
10. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.
Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F
Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer.
Mullenger JL; Zeidler MP; Fragiadaki M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629022
[TBL] [Abstract][Full Text] [Related]
12. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
[TBL] [Abstract][Full Text] [Related]
13. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
[TBL] [Abstract][Full Text] [Related]
14. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
[TBL] [Abstract][Full Text] [Related]
16. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
[TBL] [Abstract][Full Text] [Related]
18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
19. ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells.
Machado-Neto JA; Lazarini M; Favaro P; de Melo Campos P; Scopim-Ribeiro R; Franchi Junior GC; Nowill AE; Lima PR; Costa FF; Benichou S; Olalla Saad ST; Traina F
Biochim Biophys Acta; 2015 Mar; 1853(3):583-93. PubMed ID: 25523139
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
